Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives Average Recommendation of "Buy" from Analysts

Key Points

• Aquestive Therapeutics, Inc. has received a consensus rating of "Buy" from seven brokerages, with an average target price of $10.14 for the next year.
• Institutional investors hold 32.45% of Aquestive Therapeutics' stock, with several acquiring new positions recently.
• The company reported a quarterly loss of ($0.24) EPS and revenue of $8.72 million, missing analysts' expectations for both metrics.

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST - Get Free Report) have received an average rating of "Buy" from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $10.1429.

Several brokerages have recently weighed in on AQST. HC Wainwright restated a "buy" rating and set a $10.00 price objective on shares of Aquestive Therapeutics in a research report on Tuesday, June 17th. Oppenheimer assumed coverage on shares of Aquestive Therapeutics in a research report on Monday, June 2nd. They issued an "outperform" rating and a $7.00 price target for the company.

Aquestive Therapeutics Stock Performance

NASDAQ AQST traded down $0.04 during trading on Friday, reaching $3.91. 324,363 shares of the company's stock were exchanged, compared to its average volume of 1,499,666. The company has a 50 day moving average price of $3.63 and a two-hundred day moving average price of $3.10. The stock has a market cap of $387.88 million, a P/E ratio of -6.62 and a beta of 1.99. Aquestive Therapeutics has a 1 year low of $2.12 and a 1 year high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The firm had revenue of $8.72 million during the quarter, compared to analyst estimates of $12.23 million. Research analysts forecast that Aquestive Therapeutics will post -0.46 EPS for the current fiscal year.

Institutional Investors Weigh In On Aquestive Therapeutics

Several hedge funds have recently made changes to their positions in the business. Deutsche Bank AG lifted its position in Aquestive Therapeutics by 63.9% during the 4th quarter. Deutsche Bank AG now owns 61,989 shares of the company's stock worth $221,000 after acquiring an additional 24,170 shares during the period. Raymond James Financial Inc. acquired a new stake in shares of Aquestive Therapeutics during the fourth quarter worth $498,000. Two Sigma Investments LP increased its stake in Aquestive Therapeutics by 31.5% in the 4th quarter. Two Sigma Investments LP now owns 175,952 shares of the company's stock valued at $626,000 after buying an additional 42,160 shares during the period. Harvey Capital Management Inc. raised its position in Aquestive Therapeutics by 86.8% during the 1st quarter. Harvey Capital Management Inc. now owns 499,570 shares of the company's stock worth $1,449,000 after buying an additional 232,180 shares during the last quarter. Finally, ProShare Advisors LLC lifted its stake in shares of Aquestive Therapeutics by 79.8% in the 4th quarter. ProShare Advisors LLC now owns 25,232 shares of the company's stock worth $90,000 after acquiring an additional 11,200 shares during the period. Institutional investors and hedge funds own 32.45% of the company's stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.